Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.65 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.65 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11666037 | 0.83 | CYP11B1 (0.51) | CYP11B1CYP11B2KMT2A | |
| SCHEMBL21803731 | 0.82 | CYP11B1 (0.48) | CYP11B1CYP11B2PDE10A | |
| SCHEMBL2715366 | 0.82 | CYP11B1 (0.70) | CYP11B1CYP11B2PDE10A | |
| SCHEMBL20930986 | 0.80 | MET (0.51) | CYP11B1CYP11B2PDE10AKMT2A | |
| SCHEMBL2719805 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2PDE10A | |
| SCHEMBL2258454 | 0.78 | CYP11B1 (0.49) | CYP11B1CYP11B2 | |
| SCHEMBL25076210 | 0.76 | CYP11B2 (0.47) | CYP11B1CYP11B2PDE10A | |
| SCHEMBL3822233 | 0.76 | CYP11B2 (0.47) | CYP11B1CYP11B2PDE10A | |
| SCHEMBL9572666 | 0.76 | CYP11B2 (0.47) | CYP11B1CYP11B2 | |
| SCHEMBL13058960 | 0.76 | CYP11B2 (0.47) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115286572-B | 4-acyl-isoquinoline derivative and preparation method and application thereof | 绍兴文理学院 | 2023-10-13 | — | — | CN | disclosed |
| CN-115286572-A | 4-acyl-isoquinoline derivative and preparation method and application thereof | 绍兴文理学院 | 2022-11-04 | — | — | CN | disclosed |
| US-9206193-B2 | Substituted norindenoisoquinolines, syntheses thereof, and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2528440-A1 | SUBSTITUTED NORINDENOISOQUINOLINES, SYNTHESES THEREOF, AND METHODS OF USE | Purdue Research Foundation (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120302563-A1 | SUBSTITUTED NORINDENOISOQUINOLINES, SYNTHESES THEREOF, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2011094416-A1 | SUBSTITUTED NORINDENOISOQUINOLINES, SYNTHESES THEREOF, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
| EP-0498722-B1 | Bicyclic nitrogen compounds, their preparation, intermediates obtained, their use as pharmaceuticals and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1997-07-30 | — | — | EP | disclosed |
| EP-0042659-B1 | 5,6,6A,7-TETRAHYDRO-4H-DIBENZ(DE,G)ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1984-08-29 | — | — | EP | disclosed |
| US-4425350-A | 5,6,6a,7-Tetrahydro-4H-dibenz(de,g)-isoquinoline derivatives, and their use for treating central nervous system disorders | WARNER-LAMBERT COMPANY (US) | 1984-01-10 | — | — | US | disclosed |
| EP-0042659-A1 | 5,6,6a,7-Tetrahydro-4H-dibenz(de,g)isoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1981-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302563-A1 | SUBSTITUTED NORINDENOISOQUINOLINES, SYNTHESES THEREOF, AND METHODS OF USE | TOP2A, TOP1, TOP2B | CYP11B1 53/4885CYP11B2 43/4885PDE10A 1816/4885 |
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | CYP11B1 112/4885CYP11B2 26/4885PDE10A 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.